Back to search

University of Thessaly (UTH)

Μελέτη νέων αυτοαντισωμάτων ως βιοδείκτες αυτοάνοσων νευρολογικών νοσημάτων

Abstract

dc:description

Autoimmune neurological diseases are rare diseases with great heterogeneity in the clinical phenotype of patients. The use of specific biomarkers is an important tool for their diagnosis. Among the most well-studied autoimmune disorders are those induced by autoantibodies. Autoantibodies have a pathogenic role mainly when they target cell-membrane antigens such as acetylcholine receptor and MOG-glycoprotein. The present study aims to develop and use improved techniques to detect potentially pathogenic antibodies against a3 and a4 neuronal nAChR and MOG glycoprotein, specific for autoimmune neurological diseases such as autoimmune autonomic ganglionopathy (AAG), autoimmune encephalitis (AES) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Neuronal nicotinic acetylcholine receptors (nAChRs) are distinguished in many subtypes and are involved in many functions such as memory, learning, movement control and analgesia. Their loss or dysfunction is associated with many neurological and neuropsychiatric diseases. Antibodies against a3-nAChR may have pathogenic properties which cause synaptic transmission alteration in sympathetic, parasympathetic and enteric ganglia. Such antibodies have been found in patients with AAG, however low levels of antibodies against a3-nAChRs have been detected in various neurological diseases with unknown clinical and therapeutic implications. The use of the radioimmunoprecipitation assay (RIPA) is the method widely used to diagnose AAG, however its specificity is limited as approximately 50% of patients with low levels of α3-nAChR antibodies present a variety of disorders other than AAG. For this reason, we developed a cell-based assay (CBA) which specifically detects only pathogenic antibodies of AAG. The use of NACHO and RIC3 chaperones, the removal of tag sequences from the receptors (myc flag and GFP) as well as the addition of nicotine, helped to increase the expression of α3-nAChR. We studied sera from 55 patients from Greece, suspected for autonomic failure, and 13 patients from Italy, diagnosed with autonomic failure and positive for anti-α3 by RIPA. In addition, sera from 52 patients with Ca2+ channel or Hu antibodies and from 2,628 controls with various neuroimmune diseases were included. Of the 25 patients positive for anti-α3 by RIPA, 15 were positive by the CBA we developed and are also clinically confirmed to belong to AAG, while the rest had other neurological diseases. In addition, antibodies againsts α4β2-nAChR are candidate autoantigens in autoimmune encephalopathy syndrome (AES), a spectrum of neurological diseases characterized by rapid onset of mental confusion, cognitive impairment, seizures, and psychiatric symptoms. Based on the α3β2-nAChR CBA, we improved the detection method of potentially pathogenic α4β2-nAChR antibodies to identify autoantibodies in "orphan" AES cases. The study involved the screening of sera from 1752 sera of patients from Greece, Turkey and Italy who requested testing for AES and 1203 sera of 'control' patients with other neuropsychiatric diseases. 3 patients tested positive for antibodies against α4β2-nAChR. The specific clinical features of the 3 positive patients coincided with the spectrum of AES. Furthermore, in the second part of this study, we interested in MOGAD. MOGAD is an inflammatory demyelinating condition in which anti-MOG testing is an important tool in the laboratory diagnosis of the disease. However, because anti-MOG are also detected in other demyelinating diseases, it is important to have an improved CBA to avoid false-positive and false-negative results. Investigating the clinical and radiological spectrum of 21 patients positive for IgG1 anti-MOG, identified in a Greek cohort of 426 patients, "suspected" of MOGAD, and comparing the three most commonly used CBAs for the detection of anti-MOG (live IgG-CBA, live IgG1-CBA and commercial CBA), we concluded that live IgG1-CBA is superior in specificity over the others. The 21 MOG-positive patients were characterized in depth and had the clinical and radiological features associated with MOGAD.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Karagiorgou, Aikaterini
  • Καραγιώργου, Αικατερίνη

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/56010

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Karagiorgou, Aikaterini; Καραγιώργου, Αικατερίνη. Μελέτη νέων αυτοαντισωμάτων ως βιοδείκτες αυτοάνοσων νευρολογικών νοσημάτων. University of Thessaly (UTH), 2024. http://hdl.handle.net/10442/hedi/56010